Search research articles
Contact Us
Filters
Showing results (1-10 of 9) with videos related to
Page
of 1
Sort By:
Expert Opinion on Investigational Drugs
|
June 11, 2021
Therapies in preclinical and clinical development for Angelman syndrome
Theodora Markati, Jessica Duis, Laurent Servais
Orphanet Journal of Rare Diseases
|
August 2, 2023
The use of digital outcome measures in clinical trials in rare neurological diseases: a systematic literature review
Margaux Poleur, Theodora Markati, Laurent Servais
Expert Opinion on Investigational Drugs
|
March 22, 2022
Risdiplam: an investigational survival motor neuron 2 (SMN2) splicing modifier for spinal muscular atrophy (SMA)
Theodora Markati, Gemma Fisher, Sithara Ramdas, et al.
Frontiers in Pharmacology
|
November 18, 2021
Lessons Learned from Discontinued Clinical Developments in Duchenne Muscular Dystrophy
Theodora Markati, Liesbeth De Waele, Urlike Schara-Schmidt, et al.
CNS Drugs
|
July 14, 2026
Emerging Therapies for Angelman Syndrome
Cyril Tychon, Theodora Markati, Serpil Alkan, et al.
The Lancet. Neurology
|
July 19, 2022
Emerging therapies for Duchenne muscular dystrophy
Theodora Markati, Maryam Oskoui, Michelle A Farrar, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
October 3, 2022
A systematic review of adeno-associated virus gene therapies in neurology: the need for consistent safety monitoring of a promising treatment
Rebecca H Horton, Dimah Saade, Theodora Markati, et al.
Expert Opinion on Therapeutic Targets
|
December 16, 2022
Early clinical and pre-clinical therapy development in Nemaline myopathy
Gemma Fisher, Laurane Mackels, Theodora Markati, et al.
Archives of Disease in Childhood. Fetal and Neonatal Edition
|
December 21, 2018
Therapeutic hypothermia for mild neonatal encephalopathy: a systematic review and meta-analysis
Ujwal Kariholu, Paolo Montaldo, Theodora Markati, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 9) with videos related to
Sort By:
Page
of 1
Expert Opinion on Investigational Drugs
|
June 11, 2021
Therapies in preclinical and clinical development for Angelman syndrome
Theodora Markati, Jessica Duis, Laurent Servais
Orphanet Journal of Rare Diseases
|
August 2, 2023
The use of digital outcome measures in clinical trials in rare neurological diseases: a systematic literature review
Margaux Poleur, Theodora Markati, Laurent Servais
Expert Opinion on Investigational Drugs
|
March 22, 2022
Risdiplam: an investigational survival motor neuron 2 (SMN2) splicing modifier for spinal muscular atrophy (SMA)
Theodora Markati, Gemma Fisher, Sithara Ramdas, et al.
Frontiers in Pharmacology
|
November 18, 2021
Lessons Learned from Discontinued Clinical Developments in Duchenne Muscular Dystrophy
Theodora Markati, Liesbeth De Waele, Urlike Schara-Schmidt, et al.
CNS Drugs
|
July 14, 2026
Emerging Therapies for Angelman Syndrome
Cyril Tychon, Theodora Markati, Serpil Alkan, et al.
The Lancet. Neurology
|
July 19, 2022
Emerging therapies for Duchenne muscular dystrophy
Theodora Markati, Maryam Oskoui, Michelle A Farrar, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
October 3, 2022
A systematic review of adeno-associated virus gene therapies in neurology: the need for consistent safety monitoring of a promising treatment
Rebecca H Horton, Dimah Saade, Theodora Markati, et al.
Expert Opinion on Therapeutic Targets
|
December 16, 2022
Early clinical and pre-clinical therapy development in Nemaline myopathy
Gemma Fisher, Laurane Mackels, Theodora Markati, et al.
Archives of Disease in Childhood. Fetal and Neonatal Edition
|
December 21, 2018
Therapeutic hypothermia for mild neonatal encephalopathy: a systematic review and meta-analysis
Ujwal Kariholu, Paolo Montaldo, Theodora Markati, et al.
Page
of 1